Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2024-07-15 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
关于公司部分董事、高级管理人员减持股份的预披露公告
Director's Dealing Classification · 100% confidence The document is a pre-disclosure announcement regarding the planned reduction of shares held by a company director and senior management (specifically, a director and vice general manager named Xia Xinqun). It details the number of shares to be sold, the reasons for the sale, the method, and the timing. This type of document is a report of personal share transactions by company directors and executives, which fits the definition of a Director's Dealing filing. The document is not an earnings release, annual report, or any other financial report, but a specific announcement about insider share transactions.
2024-07-15 Chinese
关于持股5%以上股东减持股份预披露公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding a planned reduction in shareholding by a shareholder holding more than 5% of the company's shares. It details the shareholder's identity, the number and percentage of shares to be reduced, the methods and timing of the reduction, and related commitments and risk disclosures. There are no financial statements, earnings data, or management discussion of results. The document is a regulatory disclosure about a significant shareholder's intention to sell shares, which fits the definition of a Major Shareholding Notification (MRQ). The document length is 2659 characters, which is typical for such announcements. Therefore, the correct classification is MRQ with high confidence.
2024-07-12 Chinese
关于2024年第二季度可转换公司债券转股情况公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the conversion of convertible bonds into shares for the second quarter of 2024 by Zhejiang Tailin Biotechnology Co., Ltd. It details the bond issuance, conversion prices adjustments, and the resulting changes in share capital. The document is relatively short (3767 characters) and focuses on reporting the bond conversion activity and share capital changes, which is typical for a capital/financing update. There is no indication that this is a full financial report, audit report, or earnings release. It is not a report publication announcement since it contains substantive data about bond conversions and share changes. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2024-07-01 Chinese
浙江泰林生物技术股份有限公司向不特定对象发行可转换公司债券受托管理事务报告（2023年度）
Audit Report / Information Classification · 95% confidence The document is a detailed report titled "浙江泰林生物技术股份有限公司 向不特定对象发行可转换公司债券 受托管理事务报告 (2023年度)" which translates to "Zhejiang Tailin Bioengineering Co., Ltd. Trustee Management Report for Convertible Bonds Issued to Unspecified Objects (2023 Annual)". It includes comprehensive information about the convertible bonds issuance, bond terms, interest rates, conversion prices, bondholder meetings, bond trustee duties, bond rating updates, financial data for 2023, and detailed usage of raised funds. The document is lengthy (15,000 characters) and contains substantive financial data, bond issuance details, and management oversight information. It is not a simple announcement or certification but a full trustee management report covering the bond issuance and related financial and operational details for the year 2023. This type of document corresponds to an Audit Report / Information (AR) category, as it is a standalone report related to bond issuance management, bond trustee duties, and financial oversight, distinct from a full Annual Report (10-K) or Interim Report (IR). It is not a Capital/Financing Update (CAP) because it is a comprehensive trustee management report rather than a brief update. Therefore, the best classification is AR (Audit Report / Information). FY 2023
2024-06-25 Chinese
2021年浙江泰林生物技术股份有限公司创业板向不特定对象发行可转换公司债券2024年跟踪评级报告
Regulatory Filings Classification · 95% confidence The document is a detailed credit rating report issued by CSCI Pengyuan Credit Rating Agency for Zhejiang Tailin Biotechnology Co., Ltd. regarding its 2021 convertible bonds on the Growth Enterprise Market. It includes comprehensive financial data, credit rating opinions, business and industry environment analysis, bond issuance details, and operational insights. The document is lengthy (15,000 characters) and contains substantive financial and operational information, not merely an announcement or certification. It is not an annual or interim report, earnings release, or management discussion but a specialized credit rating report. Given the nature of the content focusing on credit rating and bond tracking, it fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement and compliance document related to credit rating and bond issuance, since there is no specific category for credit rating reports in the provided taxonomy.
2024-06-18 Chinese
关于取得专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (932 characters) from Zhejiang Tailin Biotechnology Co., Ltd. about obtaining six patent certificates. It includes details about the patents but does not contain financial data, management changes, or regulatory filings related to financial performance. It is an announcement of a corporate event (patent acquisition) rather than a financial report or regulatory filing. The document is not related to any of the specific categories like Annual Report, Earnings Release, or Management Reports. It is a general corporate announcement about intellectual property, which does not fit into the more specific categories. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2024-06-03 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.